A survey in the American Journal of Radiology (issue 195:101-106) depicts today’s challenges in oncological therapy monitoring: Almost all of the approximately 300 participating radiologists confirmed the high importance of tumor measurement for therapy decisions. 86% would likely increase their tumor measurements, if optimized workflows and tools were established. Nevertheless, besides clinical trials, tumors are not always measured in clinical routine.
Diagnosed September 2009:
95% embryonal carcinoma, 4% mature teratoma, 1% yolk sac
CS2B: Beta HCG: 306, One enlarged Lymphnode (interaortocaval) 3,2x2,9cm. Good prognosis.
3x BEP, Beta HCG < 0,6, Residual Mass = One enlarged Lymphnode around 0,6x0,7cm, Bilateral L-RPLND: 28 nodes removed - 27 clear, 1 mature teratoma (the enlarged one)
All clear so far!
Sorry for my bad english